Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19 : A Randomized, Double-Blind, Placebo-Controlled Trial
Retrospective studies showed a relationship between vitamin D status and COVID-19 severity and mortality, with an inverse relation between SARS-CoV-2 positivity and circulating calcifediol levels. The objective of this pilot study was to investigate the effect of vitamin D supplementation on the length of hospital stay and clinical improvement in patients with vitamin D deficiency hospitalized with COVID-19. The study was randomized, double blind and placebo controlled. A total of 50 subjects were enrolled and received, in addition to the best available COVID therapy, either vitamin D (25,000 IU per day over 4 consecutive days, followed by 25,000 IU per week up to 6 weeks) or placebo. The length of hospital stay decreased significantly in the vitamin D group compared to the placebo group (4 days vs. 8 days; p = 0.003). At Day 7, a significantly lower percentage of patients were still hospitalized in the vitamin D group compared to the placebo group (19% vs. 54%; p = 0.0161), and none of the patients treated with vitamin D were hospitalized after 21 days compared to 14% of the patients treated with placebo. Vitamin D significantly reduced the duration of supplemental oxygen among the patients who needed it (4 days vs. 7 days in the placebo group; p = 0.012) and significantly improved the clinical recovery of the patients, as assessed by the WHO scale (p = 0.0048). In conclusion, this study demonstrated that the clinical outcome of COVID-19 patients requiring hospitalization was improved by administration of vitamin D.
| Errataetall: |
CommentIn: JPEN J Parenter Enteral Nutr. 2023 May;47(4):580-582. - PMID 36181460 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nutrients - 14(2022), 15 vom: 26. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Niet, Sophie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1406-16-2 |
|---|
| Anmerkungen: |
Date Completed 28.07.2022 Date Revised 10.05.2023 published: Electronic CommentIn: JPEN J Parenter Enteral Nutr. 2023 May;47(4):580-582. - PMID 36181460 Citation Status MEDLINE |
|---|
| doi: |
10.3390/nu14153048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344136965 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344136965 | ||
| 003 | DE-627 | ||
| 005 | 20231226022054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/nu14153048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344136965 | ||
| 035 | |a (NLM)35893907 | ||
| 035 | |a (PII)3048 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Niet, Sophie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19 |b A Randomized, Double-Blind, Placebo-Controlled Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2022 | ||
| 500 | |a Date Revised 10.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: JPEN J Parenter Enteral Nutr. 2023 May;47(4):580-582. - PMID 36181460 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Retrospective studies showed a relationship between vitamin D status and COVID-19 severity and mortality, with an inverse relation between SARS-CoV-2 positivity and circulating calcifediol levels. The objective of this pilot study was to investigate the effect of vitamin D supplementation on the length of hospital stay and clinical improvement in patients with vitamin D deficiency hospitalized with COVID-19. The study was randomized, double blind and placebo controlled. A total of 50 subjects were enrolled and received, in addition to the best available COVID therapy, either vitamin D (25,000 IU per day over 4 consecutive days, followed by 25,000 IU per week up to 6 weeks) or placebo. The length of hospital stay decreased significantly in the vitamin D group compared to the placebo group (4 days vs. 8 days; p = 0.003). At Day 7, a significantly lower percentage of patients were still hospitalized in the vitamin D group compared to the placebo group (19% vs. 54%; p = 0.0161), and none of the patients treated with vitamin D were hospitalized after 21 days compared to 14% of the patients treated with placebo. Vitamin D significantly reduced the duration of supplemental oxygen among the patients who needed it (4 days vs. 7 days in the placebo group; p = 0.012) and significantly improved the clinical recovery of the patients, as assessed by the WHO scale (p = 0.0048). In conclusion, this study demonstrated that the clinical outcome of COVID-19 patients requiring hospitalization was improved by administration of vitamin D | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a calcifediol | |
| 650 | 4 | |a cholecalciferol | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a vitamin D | |
| 650 | 7 | |a Vitamins |2 NLM | |
| 650 | 7 | |a Vitamin D |2 NLM | |
| 650 | 7 | |a 1406-16-2 |2 NLM | |
| 650 | 7 | |a Cholecalciferol |2 NLM | |
| 650 | 7 | |a 1C6V77QF41 |2 NLM | |
| 700 | 1 | |a Trémège, Mickaël |e verfasserin |4 aut | |
| 700 | 1 | |a Coffiner, Monte |e verfasserin |4 aut | |
| 700 | 1 | |a Rousseau, Anne-Francoise |e verfasserin |4 aut | |
| 700 | 1 | |a Calmes, Doriane |e verfasserin |4 aut | |
| 700 | 1 | |a Frix, Anne-Noelle |e verfasserin |4 aut | |
| 700 | 1 | |a Gester, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Delvaux, Muriel |e verfasserin |4 aut | |
| 700 | 1 | |a Dive, Anne-Francoise |e verfasserin |4 aut | |
| 700 | 1 | |a Guglielmi, Elora |e verfasserin |4 aut | |
| 700 | 1 | |a Henket, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Staderoli, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Maesen, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, Renaud |e verfasserin |4 aut | |
| 700 | 1 | |a Guiot, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalier, Etienne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nutrients |d 2009 |g 14(2022), 15 vom: 26. Juli |w (DE-627)NLM206140738 |x 2072-6643 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:15 |g day:26 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/nu14153048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 15 |b 26 |c 07 | ||